Patrick M. Forde, MD

Patrick Forde, MBBCh, and the Oncology Brothers discuss treatment practices for patients with unresectable non–small cell lung cancer.

Medical oncologists share expert perspectives on treatment paradigms for patients with early-stage NSCLC and actionable mutations.

The Oncology Brothers and Patrick Forde, MBBCh, outline immunotherapy options for patients with non–small cell lung cancer and the role of PD-L1 in informing treatment decisions.

Patrick Forde, MBBCh, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss treatment practices for patients with stage IB and beyond non–small cell lung cancer (NSCLC).

In this review, we discuss recent clinical investigations that highlight the effects of novel compounds targeting EGFR, ALK, and other receptor oncogenes, as well as the promise of immunotherapy in lung cancer CNS disease.

This management guide for non–small-cell lung cancer (NSCLC) covers the symptoms, screening, diagnosis, staging, and treatment of adenocarcinoma, squamous cell carcinoma, and large-cell carcinoma of the lung.